PRINCETON, N.J., Oct. 19, 2004 (PRIMEZONE) -- FindProfit (www.findprofit.com), an investment service that delivered a +67% audited return in 2003, announced today that it has provided to trial and paid subscribers investment analysis of the pharmaceutical sector, including coverage of Pfizer (NYSE:PFE) and Merck (NYSE:MRK).
FindProfit's investment outlook examines the pharmaceutical sector in the wake of skepticism following MRK's Vioxx-related announcement, including coverage of Bristol-Myers Squibb (NYSE:BMY) and Novartis (NYSE:NVS).
All paid and trial FindProfit subscribers can now receive immediate access to FindProfit's exclusive reports and ongoing commentary and analysis. As a trial or paid subscriber, you'll also gain access to our latest investment moves. Start your 30-day free trial today: https://www.findprofit.com/subscribe/index.php?refer=zone219
FindProfit's investment outlook examines the following questions:
-- Will PFE's Celebrex find problems similar to Vioxx?
-- Does PFE have a strong product pipeline?
-- Has PFE been unfairly punished on the MRK news?
-- On an earnings basis, does PFE have a better yield than the 10- year Treasury?
-- What near-term risks are there for PFE and other pharmaceutical companies like BMY and NVS?
-- How could the presidential election impact pharmaceutical companies?
AND MORE
Sign up now for a 30-day free trial to FindProfit and you'll gain instant access to FindProfit's in depth coverage of the media, tech, telecom and energy sectors, as well as our full "as it happens" investment commentary and comprehensive model portfolios, by clicking here: https://www.findprofit.com/subscribe/index.php?refer=zone219
Subscribers also receive access to FindProfit's Special Bonus Report, "Profiting from the Energy Squeeze: 5 Must-Own Stocks for the Next Phase of the Energy Bull Run".
Subscribers are always protected by FindProfit's 100% customer satisfaction guarantee.
FindProfit finds you winners. The service posted a +73% audited-return in 2002, audited model portfolio gains of 67%, 58%, and 34% in 2003 and model portfolio returns of approximately 13%, 9% and 1% for the first six months of 2004.
About FindProfit.com:
FindProfit.com is a leading publisher and provider of lively, fun, and profitable investment commentary for individual investors who love the stock market. As a 100% independent investment service, FindProfit's only bias is towards making its subscribers money. FindProfit's real-time "as it happens" investment service gives individual investors the edge they need to consistently beat the market. For more information or to sign up now for a free 30-day trial to FindProfit, please visit: https://www.findprofit.com/subscribe/index.php?refer=zone219
NOTE: FindProfit, LLC is not a registered broker dealer, registered investment adviser or registered research analyst.